Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials, AAML03P1 and AAML0531. | Clinical Futures

JOIN OUR MAILING LIST
BLOG

March 21, 2023

Examining the Pandemic’s Impact on Adolescent Mental Health

March 3, 2023

CHOP selected to participate in new program to disseminate and implement cutting-edge medical evidence

We are pleased to announce that the Children’s Hospital of Philadelphia (CHOP) has been selected to participate in the Health Systems Implementation Initiative (HSII), a new fun

February 22, 2023

Maternal Fetal Antibody Transfer and COVID-19

JOIN OUR MAILING LIST
BLOG

March 21, 2023

Examining the Pandemic’s Impact on Adolescent Mental Health

March 3, 2023

CHOP selected to participate in new program to disseminate and implement cutting-edge medical evidence

We are pleased to announce that the Children’s Hospital of Philadelphia (CHOP) has been selected to participate in the Health Systems Implementation Initiative (HSII), a new fun

February 22, 2023

Maternal Fetal Antibody Transfer and COVID-19

Title

Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials, AAML03P1 and AAML0531.

Year of Publication

2017

Author

Susana Raimondi

Amy Heerema-McKenney

Soheil Meshinchi

Date Published

2017 Jul 03

ISSN Number

1528-0020

DOI

10.1182/blood-2017-01-762336

Alternate Title

Blood

PMID

28674028

WATCH THIS PAGE